2 Tower Pl, Suite 800
South San Francisco
Tel: (650) 825-6140
11 articles with Pionyr Immunotherapeutics
Pionyr Immunotherapeutics, Inc announced it has begun dosing patients in its Phase 1b expansion study investigating PY159 in patients with prioritized cancer types: ovarian cancer, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), HR+HER2- breast cancer, head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC).
Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit
Presentation by Pionyr Chief Medical Officer Leonard Reyno, M.D., features leading research in modulating innate immunity to treat cancer.
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
Pionyr Immunotherapeutics, Inc., announced today that PY314, a monoclonal antibody targeting TREM2 (triggering receptor expressed on macrophages 2), was safe and well-tolerated in a Phase 1a dose-escalation study as a single agent and in combination with pembrolizumab at its label-approved dose.
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
Pionyr Immunotherapeutics, Inc. announced today that Johanna Joyce, Ph.D., Olivier Elemento, Ph.D., and Michael Quigley, Ph.D., will join Miriam Merad, Ph.D., as members of Pionyr’s Scientific Advisory Board.
Pionyr Immunotherapeutics, Inc. announced that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.
The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.
Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function
Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
PIONYR Immunotherapeutics, Inc. announced the appointment of Alicia Levey, Ph.D., as Senior Vice President and Chief Business Officer.
ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project
ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.
Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.